Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | USP19 | O94966 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18391569 | 0.87 | SLC6A2 (0.39) | P2RX7CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL12311449 | 0.84 | GAA (0.40) | P2RX7GAANPC1RAB9ACHRNB2 | |
| SCHEMBL15244580 | 0.81 | NPC1 (0.40) | GAANPC1RAB9AALOX15SMN1; SMN2 | |
| SCHEMBL16281072 | 0.80 | GAA (0.56) | GAACHRM2CHRM3NPC1RAB9A | |
| SCHEMBL22230513 | 0.80 | GAA (0.40) | GAANPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL18391585 | 0.80 | GAA (0.36) | GAANPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL772590 | 0.80 | GAA (0.36) | GAANPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL26032908 | 0.79 | PLA2G2A (0.41) | GAANPC1RAB9AALOX15SMN1; SMN2 | |
| SCHEMBL6365551 | 0.79 | — | — | |
| SCHEMBL14447305 | 0.78 | GAA (0.39) | GAANPC1RAB9AALOX15USP19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024039858-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BROADENBIO CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2023082044-A1 | 5-FORMYL HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | 暨南大学 | 2023-05-19 | — | — | WO | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230002356-A1 | COMPOUNDS AND USES THEREOF | PANO THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2022011091-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-7345178-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-4112049-A | PIPERAZINONES | THE DOW CHEMICAL COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4100256-A | TO HYDROGEN SULFIDE AND CARBON DIOXIDE | THE DOW CHEMICAL COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | P2RX7 4743/4885GAA 1842/4885CHRM2 4766/4885 |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | P2RX7 1959/4885GAA 1103/4885CHRM2 3376/4885 |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | P2RX7 1813/4885GAA 354/4885CHRM2 4293/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | P2RX7 1867/4885GAA 2947/4885CHRM2 730/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | P2RX7 1413/4885GAA 1757/4885CHRM2 4730/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | P2RX7 4563/4885GAA 3420/4885CHRM2 4814/4885 |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | P2RX7 190/4885GAA 1364/4885CHRM2 739/4885 |
| US-20230002356-A1 | COMPOUNDS AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | P2RX7 2713/4885GAA 603/4885CHRM2 4862/4885 |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDXK, CMPK1, GCK | P2RX7 291/4885GAA 2326/4885CHRM2 2459/4885 |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MAPK1, CHUK, MAPK3 | P2RX7 1272/4885GAA 4746/4885CHRM2 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.